Quantitative diffusion weighted MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma to treatment with sunitinib or Pazopanib (DIRECTS)
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms DIRECTS
- 05 Dec 2015 Planned End Date changed from 31 Dec 2015 to 31 Jan 2016 as reported by United Kingdom Clinical Research Network.
- 19 Jul 2015 Accrual to date is 33% according to United Kingdom Clinical Research Network.
- 19 Jul 2015 Planned End Date changed from 10 Oct 2014 to 31 Dec 2015, according to United Kingdom Clinical Research Network.